severe/refractory respiratory infections
Conditions
Interventions
Meropenem (3g/day) is given intravenously
Sponsors
Department of Respiratory Medicine, University of Occupational and Environmental Health, Japan
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients 20 years of age and older 2.Patients with severe/very severe pneumonia according to the Japan Respiratory Society Guidelines for the Management of Community-Acquired Pneumonia in Adults. 3.Patients with respiratory infections other than community-acquired pneumonia or hospital-acquired pneumonia with systemic inflammatory response syndrome (SIRS)
Exclusion criteria
Exclusion criteria: 1.Patients who had been treated with meropenem 2.Contraindication for meropenem 3.Liver insufficiency (elevated levels of AST/ALT more than 5 times of the upper limits) 4.Renal insufficiency (elevated levels of BUN/creatinine more than 2 times of the upper limits) 5.Patients anticipating being susceptive of convulsion after brain disorders 6.Patients deemed ineligible by the attending physicians for various reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical efficacy at the end of meropenem (3g/day) administration | — |
Countries
Japan
Contacts
Public ContactToshinori Kawanami
University of Occupational and Environmental Health, Japan Department of Respiratory Medicine
Outcome results
None listed